Cannabinoids such as ▵-9-THC and CBD can downregulate the immune response by modulating the endocannabinoid system. This modulation is relevant for the treatment of prevalent autoimmune diseases (ADs), such as multiple sclerosis (MS), systemic lupus erythematosus (SLE), diabetes mellitus type 1 (DMT1), and rheumatoid arthritis (RA). These conditions require new therapeutic options with fewer side effects for the control of the autoimmune response. Objective: to conduct a literature review of preclinical scientific evidence that supports further clinical investigations for the use of cannabinoids (natural or synthetic) as potential immunomodulators of the immune response in ADs.
https://www.cannabisclinicians.org/wp-content/uploads/2021/01/cannabis-nomenclature-kenzi-riboulet-zimouli-1.jpg 800 1200 Michelle Smith https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png Michelle Smith2021-06-03 12:07:572021-06-03 13:48:39Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases